| abstract |
The present invention provides methods of preventing, treating, managing or ameliorating disorders utilizing an integrin .alpha.v.beta.3 antagonist in combination with an HMG-CoA reductase inhibitor and/or a bisphosphonate. The present invention also encompasses methods of preventing, treating, managing or ameliorating disorders utilizing an integrin .alpha.v.beta.3 antagonist in combination with an HMG-CoA redustase inhibitor and/or a bisphosphonate, in further combination with another therapy (e.g., another prophylactic or therapeutic agent or treatment) which is not an intern .alpha.v.beta.3 antagonist, an HMG-CoA reductase inhibitor, or a bisphosphonate. In particular, the present invention provides methods of preventing, treating, managing or ameliorating inflammatory diseases, autoimmune disorders, disorders associated with aberrant expression and/or activity of intern .alpha.v.beta.3, disorders associated with abnormal bone metabolism, disorders associated with aberrant angiogenesis and cancers, or conditions associated therewith, utilizing an antibody that immunospecifically binds to intern .alpha.v.beta.3 (e.e., VITAXIN ®) in combin ation with an HMG-CoA reductase inhibitor and/or bisphosphonate, and optionally in combination with another therapy (e.g., another prophylactic or therapeutic agent or treatment) which is not an intern .alpha.v.beta.3 antagonist, an HMG-CoA reductase inhibitor, or a bisphosphotane. The present also invention encompasses compositions and articles of manufacture for use in preventing, treating, managing or ameliorating inflammatory diseases, autoimmune disorders, disorders associated with aberrant expression and/or activity of integrin .alpha.v.beta.3, disorders associated with abnormal bone metabolisme, disorders associated with aberrant angiogenesis and cancers, or conditions associated therewith. |